The state of the fight: 

Gavi inked a 550-million-dose supply deal with China’s CNBG and Sinovac.
  Bharat Biotech applied for WHO Emergency Use Listing of its inactivated vaccine.
  Cuba authorized BioFarmaCuba’s Abdala vaccine.


Approved or authorized vaccines

The U.S. FDA granted Priority Review to Pfizer/BioNTech’s Comirnaty vaccine in the companies’ bid for full licensure, the companies announced Friday.
While the press release noted a…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.



Approved or authorized vaccines
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

CARB-X announced two new investments on Tuesday. The first, worth up to $8.77 million, will go to Germany’s Helmholtz Centre for Infection Research (HZI) and the Dortmund-based Lead Discovery Center to develop a drug to prevent S. aureus-induced lung tissue damage in pneumonia patients. The second award—up to $6.31 million to a team of HZI-affiliated researchers—will fund the development of a new treatment for P. aeruginosa infections in cystic fibrosis patients.

In other news, the…


The state of the hunt:

Gavi made a preliminary deal with GSK and Sanofi, securing up to 200 million doses of their vaccine candidate for the COVAX Facility.
  British regulators began expedited reviews of vaccines from AstraZeneca and Pfizer, and South Korea also began an initial review of the AstraZeneca candidate.
  A trial of an investigational Lilly mAb failed against advanced Covid-19 cases, and a trial of a Regeneron mAb cocktail in people requiring high-flow…

The state of the hunt:

“Hundreds of thousands” have received CNBG’s inactivated vaccine candidates through China’s emergency use program.
  Russia entered supply deals with Brazil and Mexico for its Sputnik V shot as scientists questioned a Lancet study on the vaccine.
  Merck began recruitment for Phase 1/2 trials of its measles virus vector-based vaccine candidate.



Phase 3 candidates:
AstraZeneca this week paused the Phase 3…

The state of the hunt:

Vaccine candidates from Bharat Biotech, Medicago, Zydus Cadila and the University of Queensland entered Phase 1 or 1/2 trials this week.
  Inactivated candidates from CNBG entered Phase 3.
  India issued emergency approval of Biocon’s itolizumab for the treatment of coronavirus-related cytokine-release syndrome.



Clinical trials:

Moderna says 30,000-participant Phase 3 trials of its investigational mRNA vaccine…

WHO issued a detailed investment case last Friday appealing for $31.3 billion over the next 12 months—$13.7 billion of it “urgently”—to fund the three main pillars of the Access to COVID-19 Tools (ACT) Accelerator.

The ACT Accelerator’s goals include delivering 2 billion vaccine doses by the end of 2021 and supplying 245 million courses of therapeutics and 500 million tests to low- and middle-income countries by mid-2021.

The Coalition for Epidemic Preparedness Innovations, Gavi…

The state of the hunt: 

Novavax became the biggest recipient of CEPI funds for Covid-19 this week, with a new $384 million award for its recombinant protein vaccine candidate. CureVac’s mRNA vaccine candidate induced high levels of virus-neutralizing titers at a low dose in preclinical studies. Gilead announced voluntary royalty-free licenses for remdesivir with five generic drug manufacturers, and more may be in the works.



Our Covid-19…

The world saw its 1 millionth case this week as companies continued to pursue Covid-19 solutions and many moved to scale up capacity.

Essential developments included:


On vaccines, Johnson & Johnson pledged this week that it would bring an “affordable” Covid-19 shot to the public “on a not-for-profit basis” for emergency pandemic use. It announced it has identified a lead candidate—Ad26 SARS-CoV-2—plus two investigational “backups,” and said it has begun scaling…

As the United States eclipsed China in confirmed cases, more vaccines neared human trials and funders made over $330 million in new commitments to fight Covid-19.

The week’s noteworthy developments included:


On vaccines, the University of Oxford announced today that it has begun recruiting volunteers for clinical trials—set to begin in weeks—of ChAdOx1 nCov-19, its adenovirus vector-based shot.

Sanofi announced today a collaboration with Massachusetts…